Brief: Compass Therapeutics Reports Q3 Financial Results, Provides Corporate Update
09/11/2022 14:43
Nov 9 (Reuters) - Compass Therapeutics Inc. CMPX.O :
* COMPASS THERAPEUTICS REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
* COMPASS THERAPEUTICS- INITIATED PRECLINICAL TOXICOLOGY
STUDIES
FOR CTX-8371; IND FILING & FIRST IN HUMAN CLINICAL STUDY ARE
ANTICIPATED IN H1 OF 2023
* QTRLY LOSS PER SHARE $0.12
* Q3 EARNINGS PER SHARE VIEW $-0.11 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX6vl8FY
Further company coverage: CMPX.O
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback